Abstract Cholesterol: 178.89±18.59 vs 195±23.55 mg/dl; TG: 155.85±20.99 vs 178.91±38.24 mg/ dl; ALT: 55±17.49 vs 45.74±12.63 u/L. In final visit, ultrasonographic 
Introduction
NAFLD is the hepatic manifestation of metabolic syndrome. In fact, risk factors associated with NAFLD include central obesity, type-2 diabetes mellitus, insulin resistance (IR) and dyslipidemia. 1 Non-alcoholic fatty liver disease (NAFLD), is becoming recognized as a condition possibly involved in the pathogenesis of these diseases. Support for this hypothesis emerges from studies revealing that NAFLD precedes the manifestations of the metabolic derangements. 2, 3 The spectrum of NAFLD may be from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH) which may be complicated to cirrhosis and even hepatocellular carcinoma. 4, 5 The term NAFLD is used to describe a condition of fat accumulation in liver in absence of excessive alcohol consumption (< 20 g/day) and other specific causes of hepatic steatosis. NAFLD affects some 10-24% of general population and the prevalence increases upto 6 foldin obese persons. 6 NAFLD is the cause of asymptomatic elevation of ALT in up to 90% of cases. 7 Regardless of body mass index (BMI), the presence of type 2 DM significantly increases the risk and severity of NAFLD. 4, 5 Trunkal obesity is an important risk factor even in a patients with a normal BMI. 8 About half the patients with hyperlipidemia are found to have NAFLD on ultrasonography. 9 Most of the patients with NAFLD are asymptomatic at diagnosis. Common symptoms are fatigue, malaise, right upper quadrant pain or discomfort and sensation of fullness. Hepatomegaly is common. 10, 11 Other findings relate to obesity and other features of metabolic syndrome. Mild to moderate increased serum levels of aspartate aminotransferese (AST), ALT or both are the most common and often the only laboratory abnormality. The ratio of AST: ALT is usually <1 and the ratio increases as fibrosis advances. 10 Hypertriglyceridemia increases the risk of NAFLD. 9 Ultrasonography is the most widely used, allows detecting moderate and sever steatosis with a fair sensitivity and specificity only when fat on liver biopsy exceeds 33% 10 . The American Association for study of liver disease (AASLD) set the limit for diagnosis of NAFLD at fat accumulation in the liver of at least 5 to 10%. NAFLD is estimated as the percentage of fat leaden hepatocytes observed by light microscopy in liver biopsy 10 . On USG fatty infiltration of the liver produces a diffuse increase in echogenecity as compared with that of the kidneys. USG has a sensitivity of 89% and specificity of 93% in detecting steatosis and sensitivity and specificity of 77% and 89% respectively, in detecting increased fibrosis 11 .Good metabolic control in DM or dyslipidaemia is not always effective in reversing NAFLD. Weight loss shows improvement on liver test results. [12] [13] [14] [15] No medications have been proved to directly reduce or reverse liver damage independent of weight loss. Many drugs have been used with variable degree of improvements in liver function tests and hepatic histology. [16] [17] [18] [19] [20] [21] Emerging evidence confirms that NAFLD can be progressive and associated with significant morbidity and mortality. Despite efforts aimed at improving early detection and prevention, many patients are still seen at the advanced stages. ALT is the best and most reliable noninvasive method for screening NAFLD. Over the last few years, clinical trials evaluated the use insulin sensitizers in treatment of NAFLD. Mixed results, heterogeneous therapeutic approaches and the small numbers of subjects have limited their applications as clinical guideline. In the current study, we have tried to evaluate the effectiveness of the combined insulin sensitizers which would act on different receptors at the tissue level.
Methods
This open level clinical trial was carried out in the outpatient (OPD) wing of Department of Gastrointestinal, Hepatobiliary and Pancreatic Diseases (GHPD) at Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (BIRDEM), Dhaka, in the year 2010. Sixty newly detected DM and IGT patients, referred at GHPD-OPD for raised ALT and ultrasound proven NAFLD were enrolled in this study. Patients with chronic liver disease (CLD), positive HBsAg and anti-HCV and history of alcoholism were excluded from the study. All patients were on hypocaloric diet. Every alternate patients were prescribed either (Table-II & III) . Values of ALT showed significant improvements in 2 nd and 3 rd visits ( Table-IV) . The inter-group difference regarding ALT, FBG and TG were significant in every visit ( Table-V) . Though the inter-group difference regarding ABF, total cholesterol and HbA1c was not significant at 1 st visit, it became significant in subsequent visits ( Table-V) . At baseline, all patients were grade 1 fatty change or more in USG but in final visit significant improvement towards normal and more in the group treated with both metformin and pioglitazone (Table-VI) . Value expressed as percentage % and n = (number of the patients)
Discussion
Treatment strategies for NAFLD are improving the insulin resistance by weight loss, exercise and pharmacotherapy with insulin sensitizers. In our study, we have tried to evaluate and compare the efficacy of metformin and pioglitazone combination versus metformin alone for the reduction of ALT in NAFLD. Mean age of the study population was over 45 years. In a study 65.4% patients were in 40 -59 years age group. 3 As previously noted, NAFLD is the hepatic manifestation of metabolic syndrome.
Risk factors associated with NAFLD include central obesity, type2 DM, insulin resistance and dyslipidemia. 4, 23 The values of mean BMI, waist circumference, and TG in our patients clearly indicate that insulin resistance was risk factor for developing NAFLD in our population as well. In a population based study,it was found that waist circumference was recognized as a simple parameter for estimation of liver fat accumulation. It was found that presence of NAFLD correlates significantly with BMI and waist hip ratio which support our findings. 6 Over the period of 3 and 6 months follow up, both the treatment groups showed improvements in HbA1c, more in combination group which confirmed the well established issues of glucose lowering effect of metformin and pioglitazone and more powerful blood glucose lowering effect of combination of both the drugs as stated in American Diabetic Association (ADA) guideline 2012 and guideline of American College of Clinical Endocrinology (AACE) 2012. A reduction in ALT is an acceptable end point for a proof of concept of exploratory trial in NAFLD. In our trial, serum ALT showed significant improvement at 3 rd and 6 th months in both groups. These finding confirmed the beneficial effect of insulin sensitizers in NAFLD as seen in other studies. [18] [19] [20] [21] [22] These studies evaluated either metformin or thiazolidinediones versus diet and lifestyle measures and no study evaluated combination of insulin sensitizers. Our findings are in favor of combination of drugs. Abdominal ultrasonography could provide accurate information about hepatic steatosis, visceral obesity and metabolic syndrome in appearently healthy people who do not consume alcohol. 11 In our study population no patients were found to normal USG finding in baseline, but in final visit 51% patients showed normal USG with no fatty change, 84% patient were in both metformin and pioglitazone drug.
Metformin is less expensive than most other treatment modalities of NAFLD. Most studies with prolonged use of metformin have shown no or little side effects and thus can be used safely for long period of time. For pioglitazone current recommendations are that the patients should be clinically monitored and it should not be used in those with advanced congestive cardiac failure (NYHA class III and IV).
Conclusion
In conclusion, NAFLD patients treated with metformin alone and combination of metformin and pioglitazone are effective in reducing ALT and also can reverse the ultrasonographic grading of fatty change towards normal and combination is better. Not only that, the combination group had better results in improving lipid profile and glycaemic status.
However, larger, multicenter studies can be done for better and more reliable results. However, our study had some limitations. Limited numbers of patients were evaluated for a short time. Liver biopsy was not done and patients were not followed up with fibroscan or ultrasonography.
